scholarly journals Expanding access to hepatitis C treatment by improving linkage to care: Establishing a cascade of care and active linkage program for the South Karelia region in Finland

2020 ◽  
Vol 3 (4) ◽  
Author(s):  
Juha Kemppinen ◽  
Hanna‐Kaisa Anttila ◽  
Pekka Suomalainen ◽  
Sauli Vuoti
BMJ Open ◽  
2021 ◽  
Vol 11 (10) ◽  
pp. e053394
Author(s):  
Jeffrey V Lazarus ◽  
Andrea Herranz ◽  
Camila A Picchio ◽  
Marcela Villota-Rivas ◽  
Antonia Rodríguez ◽  
...  

IntroductionThe hepatitis C virus (HCV) is a highly infectious and deadly disease, affecting some 58 million people worldwide. Of the 1.13 million people living in the Balearic Islands, Spain, about 1350 individuals have untreated HCV. Of these, about 1120 (83%) are estimated to be people who use drugs (PWUD), who are one of the key at-risk groups for HCV infection globally. Carrying out micro-elimination approaches focused on this population is crucial to achieve the WHO goal of eliminating HCV by 2030. Thus, the primary objective of this study is to validate a model of care that simplifies the screening and linkage to HCV care pathways for PWUD on the Balearic Islands.Methods and analysisThis intervention study will be implemented across 17 sites, in 4 different settings: addiction service centres (n=12), non-governmental organisation centres (n=3), a mobile methadone unit and a prison, with an estimated 3725 participants. Together with the healthcare staff at each centre, the intervention protocols will be adapted, focusing on four phases: recruitment and testing; linkage to care; treatment for those who test positive; and monitoring of sustained virological response 12 weeks after treatment and reinfection. The primary outcomes will be the number of tested and treated individuals and the secondary outcomes will include individuals lost at each step in the cascade of care. Descriptive analysis and multivariable logistic regression of the data will be undertaken.Ethics and disseminationThe Hospital Clínic Barcelona, Spain, Ethics Committee approved this study on 18 February 2021 (HCB/2020/2018). Findings will be disseminated through peer-reviewed publications, conference presentations and social media. The results of this study could provide a model for targeting PWUD for HCV testing and treatment in the rest of Spain and in other settings, helping to achieve the WHO HCV elimination goal.


2018 ◽  
Vol 5 (suppl_1) ◽  
pp. S650-S650
Author(s):  
Audun Lier ◽  
Kalie Smith ◽  
Silvia Bronson ◽  
Teresa Khoo ◽  
Kerim Odekon ◽  
...  

2020 ◽  
Vol 75 ◽  
pp. 102608 ◽  
Author(s):  
Zameer Mohamed ◽  
Deyaa Al-Kurdi ◽  
Margaret Nelson ◽  
Yusuke Shimakawa ◽  
Nowlan Selvapatt ◽  
...  

PLoS ONE ◽  
2015 ◽  
Vol 10 (11) ◽  
pp. e0142770 ◽  
Author(s):  
Amanda J. Wade ◽  
Diana M. Macdonald ◽  
Joseph S. Doyle ◽  
Adam Gordon ◽  
Stuart K. Roberts ◽  
...  

2015 ◽  
Vol 2 (suppl_1) ◽  
Author(s):  
Asher Schranz ◽  
Jason Halperin ◽  
Andrea Liu ◽  
Henry Lee ◽  
Harold Horowitz ◽  
...  

2019 ◽  
Vol 70 (9) ◽  
pp. 2005-2007
Author(s):  
Brian J Mcmahon ◽  
Lisa Townshend-Bulson ◽  
Chriss Homan ◽  
Prabhu Gounder ◽  
Youssef Barbour ◽  
...  

Abstract Most persons with chronic hepatitis C virus (HCV) infection in the United States are undiagnosed or linked to care. We describe a program for the management of Alaska Native patients infection utilizing a computerized registry and statewide liver clinics resulting in higher linkage to care (86%) than national estimates (~25%).


2020 ◽  
Vol 8 (4) ◽  
pp. 261-267
Author(s):  
Chantal Gomes ◽  
Dina Ginzberg ◽  
Robert J. Wong

AbstractBackground and ObjectiveWhile highly effective hepatitis C virus (HCV) therapies exist, gaps in the cascade of care remain. Disparities in the HCV cascade are prominent among underserved safety-net populations. We aim to evaluate the HCV cascade among an urban safety-net cohort of HCV patients.MethodsWe retrospectively evaluated adults with chronic HCV to determine rates of linkage to care (LTC), retention to care, and receiving HCV treatment from 2002 to 2018. Comparisons between groups utilized Chi-square testing; comparisons of median time to LTC and HCV treatment were evaluated with Student’s t-test and analysis of variance.ResultsAmong 600 chronic HCV patients (60.7% male, 20.7% non-Hispanic white, 49.2% African American, 92.5% treatment naïve, 26.8% cirrhosis), successful LTC within one year of HCV diagnosis was 57.7%, among which, 91.6% were successfully retained into care. In those with successful LTC, 72.6% received HCV treatment, 91.8% completed treatment, and 89% achieved SVR12. Women with HCV experienced longer delays from LTC to HCV treatment (331 vs. 206 days in men, P < 0.05), as did African Americans (280 vs. 165 days in non-Hispanic whites, P < 0.05). Compared to the non-Hispanic whites, HCV treatment was lower in African Americans (70.4% vs. 74.4%, P < 0.05).ConclusionWomen with HCV experienced significant delays along the HCV cascade, with median time of over 2 years from diagnosis to treatment. African Americans also experienced significant delays along the HCV cascade of care. However, sex and race/ethnicity were not found to be significant predictors of overall LTC or treatment.


2015 ◽  
Vol 53 (08) ◽  
Author(s):  
P Buggisch ◽  
J Petersen ◽  
K Wursthorn ◽  
A Gauthier ◽  
P Atanasov

2020 ◽  
Vol 3 (1) ◽  
pp. 3-14
Author(s):  
Sophie E Cousineau ◽  
Aysegul Erman ◽  
Lewis Liu ◽  
Sahar Saeed ◽  
Lorraine Fradette ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document